Duration of estrogen replacement therapy in relation to the risk of incident myocardial infarction in postmenopausal women

Archives of Internal Medicine

Volumn 157, Issue 12, 1997, Pages 1330-1336

  Heckbert, Susan R ^a,b   Weiss, Noel S ^a   Koepsell, Thomas D ^a,b   Lemaitre, Rozenn N ^a   Smith, Nicholas L ^a   Siscovick, David S ^a   Lin, Danyu ^a   Psaty, Bruce M ^a,b  

^a UNIVERSITY OF WASHINGTON   (United States)

^b UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ARTICLE; CONTROLLED STUDY; CORONARY RISK; DRUG EFFECT; ESTROGEN THERAPY; FEMALE; HEART INFARCTION; HUMAN; MAJOR CLINICAL STUDY; POSTMENOPAUSE; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR;

EID: 0030995532     PISSN: 00039926     EISSN: None     Source Type: Journal    
DOI: 10.1001/archinte.157.12.1330     Document Type: Article

References (31)

1. Grady D, Rubin SM, Petitti DB, et al. Hormone therapy to prevent disease and prolong life in postmenopausal women. Ann Intern Med. 1992;117:1016-1037.
2. Stampfer MJ, Colditz GA. Estrogen replacement therapy and coronary heart disease: a quantitative assessment of the epidemiologic evidence. Prev Med. 1991; 20:47-63.
3. Psaty BM, Heckbert SR, Atkins D, et al. A review of the association of estrogens and progestins with cardiovascular disease in postmenopausal women. Arch Intern Med. 1993;153:1421-1427.
4. Gerhard M, Ganz P. How do we explain the clinical benefits of estrogen? Circulation. 1995;92:5-8.
5. Psaty BM, Heckbert SR, Atkins D, et al. The risk of myocardial infarction associated with the combined use of estrogens and progestins in postmenopausal women. Arch Intern Med. 1994;154:1333-1339.
6. Psaty BM, Koepsell TD, LoGerfo JP, Wagner EH, Inui TS. Beta-blockers and primary prevention of coronary heart disease in patients with high blood pressure. JAMA. 1989;261:2087-2094.
7. Psaty BM, Heckbert SR, Koepsell TD, et al. The risk of myocardial infarction associated with antihypertensive drug therapies. JAMA. 1995;274:620-625.
8. Lobo RA. Effects of hormonal replacement on lipids and lipoproteins in postmenopausal women. J Clin Endocrinol Metab. 1991;73:925-930.
9. Breslow NE, Day NE. Statistical Methods in Cancer Research. Lyon, France: International Agency for Research on Cancer; 1980.
10. Greenland S, Finkle WD. A critical look at methods for handling missing covariates in epidemiologic regression analysis. Am J Epidemiol. 1995;142:1255-1264.
11. Maclure M, Greenland S. Tests for trend and dose response: misinterpretations and alternatives. Am J Epidemiol. 1992;135:96-104.
12. Adam S, Williams V, Vessey MP. Cardiovascular disease and hormone replacement treatment: a pilot case-control study. BMJ. 1981;282:1277-1278.
13. Avila MH, Walker AM, Jick H. Use of replacement estrogens and the risk of myocardial infarction. Epidemiology. 1990;1:128-133.
14. Falkeborn M, Persson I, Adami HO, et al. The risk of acute myocardial infarction after oestrogen and oestrogen-progestogen replacement. Br J Obstet Gynaecol. 1992;99:821-828.
15. Rosenberg L, Slone D, Shapiro S, Kaufman D, Stolley PD, Miettinen OS. Non-contraceptive estrogens and myocardial infarction in young women. JAMA. 1980; 244:339-342.
16. Henderson BE, Paganini-Hill A, Ross RK. Decreased mortality in users of estrogen replacement therapy. Arch Intern Med. 1991;151:75-78.
17. Stampfer MJ, Colditz GA, Willett WC, et al. Postmenopausal estrogen therapy and cardiovascular disease: ten-year follow-up from the nurses' health study. N Engl J Med. 1991;325:756-762.
18. Rosenberg L, Palmer JR, Shapiro S. A case-control study of myocardial infarction in relation to use of estrogen supplements. Am J Epidemiol. 1993;137:54-63.
19. Folsom AR, Mink PJ, Sellers TA, Hong C-P, Zheng W, Potter JD. Hormonal replacement therapy and morbidity and mortality in a prospective study of postmenopausal women. Am J Public Health. 1995;85:1128-1132.
20. Grodstein F. Postmenopausal estrogen and progestin use and the risk of cardiovascular disease. N Engl J Med. 1996;335:453-461.
21. West SL, Savitz DA, Koch G, Strom BL, Guess HA, Hartzema A. Recall accuracy for prescription medications: self-report compared with database information. Am J Epidemiol. 1995;142:1103-1112.
22. Matthews KA, Kuller LH, Wing RR, Meilahn EN, Plantinga P. Prior to use of estrogen replacement therapy, are users healthier than nonusers? Am J Epidemiol. 1996;143:971-978.
23. Barrett-Connor E. Postmenopausal estrogen and prevention bias. Ann Intern Med. 1991;115:455-456.
24. Hemminki E, Malin M, Topo P. Selection to postmenopausal therapy by women's characteristics. J Clin Epidemiol. 1993;46:211-219.
25. Sturgeon SR, Schairer C, Brinton LA, Pearson T, Hoover RN. Evidence of a healthy estrogen user survivor effect. Epidemiology. 1995;6:227-231.
26. Felson DT, Zhang Y, Hannan MT, Kiel DP, Wilson PWF, Anderson JJ. The effect of postmenopausal estrogen therapy on bone density in elderly women. N Engl J Med. 1993;329:1141-1146.
27. Ettinger B, Grady D. The waning effect of postmenopausal estrogen therapy on osteoporosis. N Engl J Med. 1993;329:1192-1193.
28. Steinberg KK, Smith SJ, Thacker SB, Stroup DF. Breast cancer risk and duration of estrogen use: the role of study design in meta-analysis. Epidemiology. 1994; 5:415-421.
29. Colditz GA, Hankinson SE, Hunter DJ, et al. The use of estrogens and progestins and the risk of breast cancer in postmenopausal women. N Engl J Med. 1995; 332:1589-1593.
30. Stanford JL, Weiss NS, Voigt LF, Daling JR, Habel LA, Rossing MA. Combined estrogen and progestin hormone replacement therapy in relation to risk of breast cancer in middle-aged women. JAMA. 1995;274:137-142.
31. Newcomb PA, Longnecker MP, Storer BE, et al. Long-term hormone replacement therapy and risk of breast cancer in postmenopausal women. Am J Epidemiol. 1995;142:788-795.